tradingkey.logo

Nasus Pharma Ltd

NSRX
5.440USD
-0.280-4.83%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
49.28MMarktkapitalisierung
VerlustKGV TTM

Nasus Pharma Ltd

5.440
-0.280-4.83%

mehr Informationen über Nasus Pharma Ltd Unternehmen

Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.

Nasus Pharma Ltd Informationen

BörsenkürzelNSRX
Name des UnternehmensNasus Pharma Ltd
IPO-datumAug 13, 2025
CEOTeleman (Dan)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeAug 13
AddresseYigal Alon 65
StadtTEL AVIV-YAFO
BörseNASDAQ OMX – NASDAQ Basic Amex
LandIsrael
Postleitzahl- -
Telefon97237326616
Websitehttps://www.nasuspharma.com
BörsenkürzelNSRX
IPO-datumAug 13, 2025
CEOTeleman (Dan)

Führungskräfte von Nasus Pharma Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+55292.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+42854.00%
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Mr. Ronnie Hershman
Mr. Ronnie Hershman
Independent Director
Independent Director
--
--
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Isaac Israel
Isaac Israel
Independent Director Nominee
Independent Director Nominee
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+55292.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+42854.00%
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
Andere
36.92%
Aktionäre
Aktionäre
Anteil
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
Andere
36.92%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
43.95%
Corporation
21.03%
Investment Advisor
0.03%
Andere
34.99%

Institutionelle Beteiligung

Aktualisiert: Wed, Jan 21
Aktualisiert: Wed, Jan 21
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
2
3.24K
0.00%
--
2025Q4
2
2.38K
0.03%
+1.14K
2025Q3
7
5.35M
59.33%
+5.35M

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Gilboa (Udi)
1.90M
21.09%
+55.29K
+3.00%
Sep 30, 2025
Megiddo (Dalia)
1.89M
20.96%
+42.85K
+2.32%
Sep 30, 2025
Hershman Holdings L.L.C.
891.19K
9.89%
+414.18K
+86.83%
Sep 30, 2025
Capital Point Ltd
575.13K
6.38%
+575.13K
--
Aug 14, 2025
Phoenix Solutions Ltd
429.31K
4.76%
--
--
Sep 30, 2025
Krayz (Galia Temtsin)
171.72K
1.91%
+171.72K
--
Aug 12, 2025
Morgan Stanley Smith Barney LLC
2.00K
0.02%
+2.00K
--
Sep 30, 2025
UBS Financial Services, Inc.
1.24K
0.01%
+1.24K
--
Sep 30, 2025
Lapidot (Tair Ph.D.)
10.00
0%
+10.00
--
Aug 12, 2025

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI